[EN] EGFR INHIBITORS IN CANCER TREATMENT [FR] INHIBITEURS D'EGFR DANS LE TRAITEMENT DU CANCER
摘要:
The present invention is directed to the compounds of Formula (A) inhibitors of EGFR. The inhibitors described herein can be useful in the treatment of diseases or disorders associated with EGFR, such as is lung cancer. In particular, the invention is concerned with compounds and pharmaceutical compositions inhibiting EGFR kinase activity in a cell, methods of treating diseases or disorders associated with EGFR, and methods of synthesizing these compounds.
Dialkyl acetals containing other functional groups can participate in stereoselective coupling reactions with chiral titanium enolates. Such an approach provides the protected γ-amino acid present in bistramides and FR252921 in a highly efficient manner.
Influence of Alkoxy Groups on Rates of Acetal Hydrolysis and Tosylate Solvolysis: Electrostatic Stabilization of Developing Oxocarbenium Ion Intermediates and Neighboring-Group Participation To Form Oxonium Ions
作者:Angie Garcia、Douglas A. L. Otte、Walter A. Salamant、Jillian R. Sanzone、K. A. Woerpel
DOI:10.1021/acs.joc.5b00338
日期:2015.5.1
that do not have an alkoxy group. Rate accelerations are largest when the two functional groups are linked by a flexible cyclic tether. When controlled for the inductive destabilization, an alkoxy group can accelerate acetal hydrolysis by up to 200-fold. The difference in rates of acetal hydrolysis between a substrate where the alkoxy group was tethered to the acetal group by a five-membered ring compared
Lipids and lipid compositions for the delivery of active agents
申请人:Novartis AG
公开号:US10426737B2
公开(公告)日:2019-10-01
This invention provides for a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1-R3, n, p, L1 and L2 are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.